Big Money Sentiment Indicator of Bristol Myers Squibb Co (NYSE:BMY) Falls in 2017 Q4 to 0.94

May 16, 2018 - By Mark Mitchell

Bristol-Myers Squibb Company (NYSE:BMY) Corporate Logo

Bristol Myers Squibb Co’s Sentiment

“Big money sentiment for Bristol Myers Squibb Co (NYSE:BMY) in 2017 Q4 decreased to 0.94, according to SEC.gov filings. So its down -0.09, from 2017Q3’s 1.03. 563 institutional investors increased or opened new equity positions, while 598 sold and reduced their equity positions in Bristol Myers Squibb Co so the sentiment dived. Funds own 1.11 billion shares, up from 1.11 billion shares in 2017Q3. Funds holding Bristol Myers Squibb Co in top 10 decreased from 45 to 36 for a decrease of 9. In total 72 funds closed positions, 526 reduced and 457 increased. Also 106 funds bought new Bristol Myers Squibb Co stakes.

Biggest Bristol Myers Squibb Co Investors

Terril Brothers Inc. owns 505,594 shares in Bristol Myers Squibb Co as of 2017 Q4. Bristol Myers Squibb Co’s shareholder Healthinvest Partners Ab owns 43,400 shares as of 2017 Q4. Sabby Management Llc reported 931,807 shares. The New Jersey-based fund Blackhill Capital Inc have invested about 5.16% of the investment manager’s stock portfolio in Bristol Myers Squibb Co. The New York-based fund Opus Point Partners Management Llc holds 90,000 shares or 4.77% of their long stock exposure.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide.The firm is worth $85.30 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection .The P/E ratio is 85.52. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

BMY reached $52.17 during the last trading session after $0.13 change.Currently Bristol-Myers Squibb Company is uptrending after 11.37% change in last May 16, 2017. BMY has also 3.65M shares volume. BMY underperformed by 0.18% the S&P 500.

Earnings report for Bristol-Myers Squibb Company (NYSE:BMY) is awaited on July, 26., Zacks reports. Analysts forecast 16.22 % diference or $0.86 from the $0.74 EPS from 2017. If reported the P/E will be 15.17 with $1.41B profit. After $0.94 earnings per share was published previous quarter, analysts now see negative EPS growth of -8.51 % for Bristol-Myers Squibb Company.

Quantitative Systematic Strategies Ltd Com holds 37,405 shs. Becker Capital Incorporated holds 0.01% or 6,841 shs. Tocqueville Asset Management Ltd Partnership invested 0.46% of its capital in Bristol-Myers Squibb Company (NYSE:BMY). Loring Wolcott & Coolidge Fiduciary Advsr Ltd Liability Partnership Ma stated it has 0.04% of its capital in Bristol-Myers Squibb Company (NYSE:BMY). Cliftonlarsonallen Wealth Advsr Limited Liability Corporation holds 0.15% or 23,526 shs. Telos Capital Management has 0.3% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 14,109 shs. Hightower Limited Liability Company owns 1.08 million shs. Daiwa Securities Gp Inc invested in 151,447 shs or 0.07% of the stock. Parthenon Limited Liability Corp accumulated 0.15% or 10,640 shs. 5,403 were reported by Sns Gp Lc. Robeco Institutional Asset Management Bv invested in 350,991 shs or 0.11% of the stock. Carret Asset Management Limited Liability Company reported 41,002 shs or 0.39% of all its holdings. Country Club Trust Na holds 25,919 shs. Wells Fargo & Mn invested in 9.21 million shs. South Dakota Inv Council has invested 0.12% of its capital in Bristol-Myers Squibb Company (NYSE:BMY).

Bristol-Myers Squibb Company had 1 sale and 2 insider purchases since December 12, 2017. This’s net activity of $163,963. On Tuesday, December 12 $335,172 worth of stock was sold by Lynch Thomas J. Jr.. 4,000 shs were bought by Samuels Theodore R. II, worth $249,187 on Friday, December 15.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Total analysts of 11 have positions in Bristol Myers (NYSE:BMY) as follows: 4 rated it a “Buy”, 0 with “Sell” and 7 with “Hold”. The positive are 36%. Since February 6, 2018 according to StockzIntelligence Inc Bristol Myers has 17 analyst reports. On Wednesday, April 18 the stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Underperform” rating by BMO Capital Markets. On Monday, March 5 Bank of America maintained Bristol-Myers Squibb Company (NYSE:BMY) rating. Bank of America has “Neutral” rating and $68 target. On Tuesday, February 6 the stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Buy” rating given by Leerink Swann. On Tuesday, April 17 Morgan Stanley downgraded the shares of BMY in report to “Equal-Weight” rating. On Tuesday, April 17 the stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Neutral” rating by Bank of America. On Tuesday, February 6 the rating was maintained by BMO Capital Markets with “Underperform”. In Friday, March 23 report Jefferies maintained it with “Hold” rating and $7000 target. On Friday, April 13 the stock has “Hold” rating by Jefferies. On Friday, April 27 the firm earned “Market Perform” rating by BMO Capital Markets. In Monday, February 26 report Jefferies maintained it with “Hold” rating and $72.0 target.

A couple more Bristol-Myers Squibb Company (NYSE:BMY) news were brought out by: Fool.com which released on May 09, 2018 “Why Bristol-Myers Squibb Stock Crashed in April”, also Seekingalpha.com on May 16, 2018 brought out “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)”, the next Seekingalpha.com is “Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise” on May 16, 2018. Bizjournals.com has article titled “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer”.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: